Atossa Therapeutics (ATOS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ATOS Atossa Therapeutics

Watchlist

0.9637
-0.0163-1.66%

Close Dec 20 16:00 ET

0.9901
+0.0264+2.74%

Post 19:36 ET

121.23MMarket Cap-4.59P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsDec 12 12:31 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Buy on Atossa Therapeuticsto Buy
BenzingaDec 12 12:25 ET
Atossa Therapeutics Analyst Ratings
BenzingaDec 12 12:24 ET · Ratings
Express News | Atossa Therapeutics To Present Data Describing the Discovery of Compounds That May Be Synergistic With (Z)-Endoxifen And That Could Potentially Be Used in Combinations For The Treatment Of Breast Cancer. The Data Will Be Presented In A Poster At The...
BenzingaDec 12 08:20 ET
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic With (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Atossa TherapeuticsDec 12 00:00 ET
Atossa Therapeutics Announces Full Result From KARISMA-Endoxifen Trial
TipRanksDec 11 08:20 ET

Comments

Jaguar8

Dec 12 07:17

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Atossa Therapeutics (NASDAQ: ATOS)has announced groundbreaking research findings on compounds that work synergistically with (Z)-endoxifen for breast cancer treatment. The discovery, presented at the 2024 San Antonio Breast Cancer Symposium, utilized both insilico and chemic...

Jaguar8

Dec 11 07:18

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Wednesday, 11th December at 8:15 am
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer
Data to be Presented in a Poster Spotlight Session During the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 11, 202...

Jaguar8

Dec 10 08:05

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
Tuesday, 10th December at 9:05 am
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today ann...